EPI Health and MC2 Therapeutics announce U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)
POSTED: July 19, 2021
Now available: Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age or older introduces use of PAD™ ...
READ FULL ARTICLE >
Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to WYNZORA® Cream for treatment of Plaque Psoriasis
POSTED: February 17, 2021
In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
